"Survival Rate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Descriptor ID |
D015996
|
MeSH Number(s) |
E05.318.308.985.550.900 N01.224.935.698.826 N06.850.505.400.975.550.900 N06.850.520.308.985.550.900
|
Concept/Terms |
Survival Rate- Survival Rate
- Rate, Survival
- Rates, Survival
- Survival Rates
Mean Survival Time- Mean Survival Time
- Mean Survival Times
- Survival Time, Mean
- Survival Times, Mean
- Time, Mean Survival
- Times, Mean Survival
Cumulative Survival Rate- Cumulative Survival Rate
- Cumulative Survival Rates
- Rate, Cumulative Survival
- Rates, Cumulative Survival
- Survival Rate, Cumulative
- Survival Rates, Cumulative
|
Below are MeSH descriptors whose meaning is more general than "Survival Rate".
Below are MeSH descriptors whose meaning is more specific than "Survival Rate".
This graph shows the total number of publications written about "Survival Rate" by people in this website by year, and whether "Survival Rate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 0 | 1 | 1 |
1998 | 0 | 1 | 1 |
2000 | 0 | 1 | 1 |
2003 | 0 | 1 | 1 |
2004 | 0 | 2 | 2 |
2005 | 0 | 1 | 1 |
2009 | 0 | 2 | 2 |
2010 | 0 | 1 | 1 |
2011 | 0 | 2 | 2 |
2012 | 0 | 2 | 2 |
2013 | 0 | 4 | 4 |
2014 | 0 | 3 | 3 |
2016 | 0 | 2 | 2 |
2017 | 0 | 3 | 3 |
2018 | 0 | 1 | 1 |
2019 | 0 | 3 | 3 |
2020 | 0 | 2 | 2 |
2021 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Survival Rate" by people in Profiles.
-
Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns. Leukemia. 2022 01; 36(1):80-89.
-
Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance. Blood. 2021 04 29; 137(17):2347-2359.
-
The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells. Cells. 2021 04 28; 10(5).
-
Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. BMC Cancer. 2020 Nov 11; 20(1):1091.
-
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial. Breast Cancer Res. 2020 10 23; 22(1):111.
-
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(=3) chemotherapy - The GCIG symptom benefit study (SBS). Gynecol Oncol. 2020 01; 156(1):45-53.
-
Presence of centromeric but absence of telomeric group B KIR haplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALL. Bone Marrow Transplant. 2019 11; 54(11):1847-1858.
-
Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. J Natl Cancer Inst. 2019 04 01; 111(4):380-387.
-
Daunorubicin during delayed intensification decreases the incidence of infectious complications - a randomized comparison in trial CoALL 08-09. Leuk Lymphoma. 2019 01; 60(1):60-68.
-
Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer. Sci Rep. 2017 12 11; 7(1):17307.